Widespread exposure to GLP-1RAs and weight loss-related discourse: Considering potential public health implications.

Canadian journal of public health = Revue canadienne de sante publique

The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors.

Cell metabolism

Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes.

Diabetes therapy : research, treatment and education of diabetes and related disorders

Tirzepatide versus dulaglutide in heart failure: another SURPASS attempt yielding a tie.

Heart failure reviews

Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus.

Journal of the American College of Cardiology

The ESSENCE of hope: what semaglutide's Food and Drug Administration approval means for metabolic dysfunction-associated steatohepatitis.

Hepatobiliary surgery and nutrition

GLP-1 Receptor Agonist Semaglutide and SGLT2 Inhibitors after Acute Coronary Syndrome in Patients with Diabetes: Real-World Comparative Outcomes from an Observational Registry.

Cardiology

Glucagon-Like Peptide-1 Receptor Agonist Utilization Among Sleep Surgery Clinic Patients.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery

New blog live on PeptiDex discussing the new FDA Peptide Reclassifications for 2026! It discusses the 14 peptides (BPC-157, Ipamorelin, CJC-1295, GHK-cu, MOTS-c, Selank, Semax, +++) which will be re-legalized & what exactly it entails! vvv https://t.co/k3P9TalgOf https://t.co/30qiSVu9qv

since we're on the subject, here are some issues with GLP-1 (noting the legend), aka Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), Zepbound (tirzepatide), and Trulicity (dulaglutide) https://t.co/rjvFWumuDp

On July 23–24, 2026, an FDA advisory committee will evaluate whether multiple peptide substances—BPC-157, KPV, TB-500, MOTS-C, emideltide (DSIP), semax, and epitalon—should be added to the 503A compounding list, including review of proposed uses and sponsor presentations.

Wait a minute! I'm sure FDA continues to see other unapproved but popular peptide drugs like BPC-157 continuing to be marketed. These can be risky & ineffective too. Are you going to go after companies violating regs on peptide drugs or cave into RFK Jr. on their compounding? https://t.co/yhJ7DX7wAH

• HHS Secretary Kennedy just announced the FDA is removing 12 key peptides from Category 2 restrictions starting with BPC-157 and others moving to full scientific review. • $HIMS is not a GLP-1 only company. The entire peptide industry stands ready to boom as regulated access https://t.co/3HzcTJWfS0 https://t.co/9UySm2FWBU

@LeRoi__Bear @TheDrMAWZ @sarasteinmd BPC-157: Synthetic stomach peptide promoting angiogenesis and repair. Strong animal data for tendon/wound/gut healing, NSAID alternative; limited human trials, unapproved. Rare sides, mostly none reported. GLP-1 agonists (semaglutide etc.): Curb cravings/appetite. Emerging

@newstart_2024 The infrastructure argument here is solid, but this tweet skips the part that actually matters for policy: the difference between GLP-1 agonists and something like BPC-157 is not just regulatory status, it is the entire evidentiary architecture behind them. Semaglutide has

Common GLP 1 agents: •Semaglutide (Ozempic, Wegovy) •Liraglutide (Victoza, Saxenda) •Dulaglutide (Trulicity) •Exenatide (Byetta, Bydureon) •Tirzepatide (Mounjaro, Zepbound), a dual GLP-1 and GIP agonist with greater potency